The company’s two-dose vaccine wasn’t expected to suddenly boost vaccination rates, and it hasn’t. Novavax’s vaccine has similar efficacy to Pfizer’s and Moderna’s options but is protein-based rather than mRNA-based, which could appeal to the 10,000 or so Americans who have chosen it since its July 19 approval.
Novavax submitted an emergency use authorization application Aug. 15 to the FDA along with data showing the third dose resulted in a “significant antibody response,” Novavax said.
